Legend Biotech Corporation LEGN
18.21 USD -1.34 (-6.83%)
Nov 12, 2026, 9:39 AM EST
18.04 Day range 19.10
16.24 52-week range 37.50
- YTD
- -16.26%
- 1 year
- -41.59%
News
benzinga.com Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25 Oppenheimer analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Perform and lowers the price target from $40 to $25.
benzinga.com Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $43 Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $43.- benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $61 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $68 to $61.
benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $50 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $56 to $50.
seekingalpha.com Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
marketbeat.com What Legend Biotech (LEGN) Said on Its Q3 Earnings Call Legend Biotech NASDAQ: LEGN reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line…
benzinga.com Legend Biotech Q3 2026 Earnings Call Transcript Legend Biotech (NASDAQ:LEGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…- benzinga.com Legend Biotech Q3 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $359.500M Miss $361.619M Estimate Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 380 percent increase over losses of…
globenewswire.com Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of CARTITUDE-2 Cohort A patients remained alive and…
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.
benzinga.com JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33 JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.
benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.- benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
benzinga.com Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) --…- benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.
- benzinga.com Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
benzinga.com This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.- benzinga.com Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49 Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
- benzinga.com TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24 TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.
- benzinga.com Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40 Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
- benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $59 to $58.
- benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.
benzinga.com Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34)…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.- benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $59 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $63 to $59.
- benzinga.com Legend Biotech CEO Ying Huang Steps Down, Alan Bash Named Interim CEO Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and…
- benzinga.com UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28 UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers the price target from $49 to $28.
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In July Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.- benzinga.com JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announces $35 price target.
- benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $64 to $63.
benzinga.com Why Is Legend Biotech Stock Falling Thursday? Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
benzinga.com Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.
benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.- benzinga.com Legend Biotech Commences $225M Offering Of Its American Depositary Shares Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of…
- benzinga.com Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated…
- benzinga.com UBS Maintains Buy on Legend Biotech, Raises Price Target to $49 UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $31 to $49.
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $65 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $50 to $65.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell Lymphoma Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignanciesAn ORR of 100%…
- benzinga.com Legend Biotech Announces First-In-Human Clinical Data For LB2102; Data, Presented At 2026 ASCO, Support Clinical Potential Of CAR-T Cell Therapy In Solid Tumors LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $50 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $50 price target.
benzinga.com These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.- benzinga.com TD Cowen Maintains Hold on Legend Biotech, Raises Price Target to $29 TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and raises the price target from $21 to $29.
- benzinga.com Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $48 Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $48.
- benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Raises Price Target to $64 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target from $62 to $64.